Literature DB >> 34702739

d-mannose suppresses oxidative response and blocks phagocytosis in experimental neuroinflammation.

Jing Wang1,2,3, Negin Jalali Motlagh1,2, Cuihua Wang1,2, Gregory R Wojtkiewicz2, Stephan Schmidt2, Cindy Chau1,2, Radha Narsimhan1,2, Enrico G Kullenberg1,2, Cindy Zhu1,2, Jenny Linnoila1, Zhenwei Yao4, John W Chen5,2.   

Abstract

Inflammation drives the pathology of many neurological diseases. d-mannose has been found to exert an antiinflammatory effect in peripheral diseases, but its effects on neuroinflammation and inflammatory cells in the central nervous system have not been studied. We aimed to determine the effects of d-mannose on key macrophage/microglial functions-oxidative stress and phagocytosis. In murine experimental autoimmune encephalomyelitis (EAE), we found d-mannose improved EAE symptoms compared to phosphate-buffered saline (PBS)-control mice, while other monosaccharides did not. Multiagent molecular MRI performed to assess oxidative stress (targeting myeloperoxidase [MPO] using MPO-bis-5-hydroxytryptamide diethylenetriaminepentaacetate gadolinium [Gd]) and phagocytosis (using cross-linked iron oxide [CLIO] nanoparticles) in vivo revealed that d-mannose-treated mice had smaller total MPO-Gd+ areas than those of PBS-control mice, consistent with decreased MPO-mediated oxidative stress. Interestingly, d-mannose-treated mice exhibited markedly smaller CLIO+ areas and much less T2 shortening effect in the CLIO+ lesions compared to PBS-control mice, revealing that d-mannose partially blocked phagocytosis. In vitro experiments with different monosaccharides further confirmed that only d-mannose treatment blocked macrophage phagocytosis in a dose-dependent manner. As phagocytosis of myelin debris has been known to increase inflammation, decreasing phagocytosis could result in decreased activation of proinflammatory macrophages. Indeed, compared to PBS-control EAE mice, d-mannose-treated EAE mice exhibited significantly fewer infiltrating macrophages/activated microglia, among which proinflammatory macrophages/microglia were greatly reduced while antiinflammatory macrophages/microglia increased. By uncovering that d-mannose diminishes the proinflammatory response and boosts the antiinflammatory response, our findings suggest that d-mannose, an over-the-counter supplement with a high safety profile, may be a low-cost treatment option for neuroinflammatory diseases such as multiple sclerosis.

Entities:  

Keywords:  zzm321990d-mannose; imaging; neuroinflammation; oxidative stress; phagocytosis

Mesh:

Substances:

Year:  2021        PMID: 34702739      PMCID: PMC8673064          DOI: 10.1073/pnas.2107663118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

Review 1.  Mannose receptor.

Authors:  S E Pontow; V Kery; P D Stahl
Journal:  Int Rev Cytol       Date:  1992

2.  Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis.

Authors:  Eileen J McMahon; Samantha L Bailey; Carol Vanderlugt Castenada; Hanspeter Waldner; Stephen D Miller
Journal:  Nat Med       Date:  2005-02-27       Impact factor: 53.440

3.  In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed.

Authors:  I D Vainchtein; J Vinet; N Brouwer; S Brendecke; G Biagini; K Biber; H W G M Boddeke; B J L Eggen
Journal:  Glia       Date:  2014-06-23       Impact factor: 7.452

4.  Isolation of brain and spinal cord mononuclear cells using percoll gradients.

Authors:  Paula A Pino; Astrid E Cardona
Journal:  J Vis Exp       Date:  2011-02-02       Impact factor: 1.355

Review 5.  Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.

Authors:  Dalia Rotstein; Xavier Montalban
Journal:  Nat Rev Neurol       Date:  2019-05       Impact factor: 42.937

6.  Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes.

Authors:  S Sugiyama; Y Okada; G K Sukhova; R Virmani; J W Heinecke; P Libby
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

Review 7.  Will the real multiple sclerosis please stand up?

Authors:  Peter K Stys; Gerald W Zamponi; Jan van Minnen; Jeroen J G Geurts
Journal:  Nat Rev Neurosci       Date:  2012-06-20       Impact factor: 34.870

8.  D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial.

Authors:  Bojana Kranjčec; Dino Papeš; Silvio Altarac
Journal:  World J Urol       Date:  2013-04-30       Impact factor: 4.226

9.  Elevated myeloperoxidase activity in white matter in multiple sclerosis.

Authors:  Elizabeth Gray; Taya Louise Thomas; Samar Betmouni; Neil Scolding; Seth Love
Journal:  Neurosci Lett       Date:  2008-08-15       Impact factor: 3.046

10.  Novel Markers to Delineate Murine M1 and M2 Macrophages.

Authors:  Kyle A Jablonski; Stephanie A Amici; Lindsay M Webb; Juan de Dios Ruiz-Rosado; Phillip G Popovich; Santiago Partida-Sanchez; Mireia Guerau-de-Arellano
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

View more
  3 in total

1.  D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.

Authors:  Ruonan Zhang; Yajing Yang; Wenjing Dong; Mingen Lin; Jing He; Xinchao Zhang; Tongguan Tian; Yunlong Yang; Kun Chen; Qun-Ying Lei; Song Zhang; Yanping Xu; Lei Lv
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-22       Impact factor: 12.779

2.  Mannose Attenuates Colitis-Associated Colorectal Tumorigenesis by Targeting Tumor-Associated Macrophages.

Authors:  Qinglong Liu; Xiaojing Li; Hao Zhang; Haitao Li
Journal:  J Cancer Prev       Date:  2022-03-30

3.  Mannose-decorated ginsenoside Rb1 albumin nanoparticles for targeted anti-inflammatory therapy.

Authors:  Zhihui Fu; Xiaohui Wang; Xuan Lu; Ying Yang; Lingling Zhao; Lin Zhou; Kaikai Wang; Hanlin Fu
Journal:  Front Bioeng Biotechnol       Date:  2022-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.